Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers.

In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants.

Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center.

Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research.

  • Education

    University of Pennsylvania School of Medicine, 2002

  • Residencies

    University of Texas Anderson Cancer Center, Radiation Oncology, 2007

  • Board Certifications

    Radiation Oncology, American Board of Radiology

  • Academic Title

    Professor

I am a passionate advocate for my patients in helping them achieve their best outcomes, both in health and quality of life.

Clinics I work with

Melanoma & Skin Cancer Program

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Radiation Oncology Clinic

See all three of our Bay Area locations.

My reviews

4.9

Overall Experience
144 Reviews
dr Yom inspires confidence in her expertise
Explained things in a way that was easy to understand
144 Reviews
Did the doctor pay attention to your concerns
144 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
137 Reviews
Knew the important information about your medical history
144 Reviews
The provider showed respect for what you had to say
143 Reviews
The provider spent enough time with me
144 Reviews

Selected research

Decorative Caduceus

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%.

Recruiting

Decorative Caduceus

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usua...

Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test.

Recruiting

Share